267 related articles for article (PubMed ID: 23596126)
1. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Vickers AJ; Ulmert D; Sjoberg DD; Bennette CJ; Björk T; Gerdtsson A; Manjer J; Nilsson PM; Dahlin A; Bjartell A; Scardino PT; Lilja H
BMJ; 2013 Apr; 346():f2023. PubMed ID: 23596126
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Vickers AJ; Cronin AM; Björk T; Manjer J; Nilsson PM; Dahlin A; Bjartell A; Scardino PT; Ulmert D; Lilja H
BMJ; 2010 Sep; 341():c4521. PubMed ID: 20843935
[TBL] [Abstract][Full Text] [Related]
3. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
4. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
5. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
6. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
8. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
10. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.
Larsen SB; Brasso K; Iversen P; Christensen J; Christiansen M; Carlsson S; Lilja H; Friis S; Tjønneland A; Dalton SO
Eur J Cancer; 2013 Sep; 49(14):3041-8. PubMed ID: 23684783
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
Ulmert D; Cronin AM; Björk T; O'Brien MF; Scardino PT; Eastham JA; Becker C; Berglund G; Vickers AJ; Lilja H
BMC Med; 2008 Feb; 6():6. PubMed ID: 18279502
[TBL] [Abstract][Full Text] [Related]
12. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
Preston MA; Batista JL; Wilson KM; Carlsson SV; Gerke T; Sjoberg DD; Dahl DM; Sesso HD; Feldman AS; Gann PH; Kibel AS; Vickers AJ; Mucci LA
J Clin Oncol; 2016 Aug; 34(23):2705-11. PubMed ID: 27298404
[TBL] [Abstract][Full Text] [Related]
13. Baseline prostate-specific antigen testing at a young age.
Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
[TBL] [Abstract][Full Text] [Related]
14. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
16. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
Heijnsdijk EAM; Gulati R; Tsodikov A; Lange JM; Mariotto AB; Vickers AJ; Carlsson SV; Etzioni R
J Natl Cancer Inst; 2020 Oct; 112(10):1013-1020. PubMed ID: 32067047
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
19. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
